Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

Delayed Quote. Delayed  - 05/24 09:46:45 am
1440.5 GBp   +0.17%
05/20DJChina Drug Deal Will Slash Prices of Top-Selling Treatments by Up..
05/19 INNOVIVA : GSK presents new data from Breo® Ellipta® SUMMIT study in..
05/18 GLAXOSMITHKLINE : GSK Presents Efficacy Data for Anoro(R) Ellipta(R)..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

GlaxoSmithKline: European Commission Authorizes Nimenix

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2012 | 02:24pm CEST

GlaxoSmithKline PLC (>> GlaxoSmithKline plc), the drug company, said Friday that the European Commission has granted marketing authorization for Nimenrix, Meningococcal group A, C, W-135 and Y conjugate vaccine, for active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y.

-Shares at 1207 GMT, up a penny, or 0.04%, at 1,420.5 pence valuing the company at GBP71.61 billion.

-By Rory Gallivan, Dow Jones Newswires; 44-20-7842-9411; rory.gallivan@dowjones.com

Stocks mentioned in the article : GlaxoSmithKline plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on GLAXOSMITHKLINE PLC
05/20DJChina Drug Deal Will Slash Prices of Top-Selling Treatments by Up to 67%
05/19 INNOVIVA : GSK presents new data from Breo® Ellipta® SUMMIT study in patients wi..
05/18 GLAXOSMITHKLINE : GSK Presents Efficacy Data for Anoro(R) Ellipta(R) in COPD Pat..
05/18 GLAXOSMITHKLINE : GSK Present New Data From Breo(R) Ellipta(R) SUMMIT Study in P..
05/18 GLAXOSMITHKLINE : Glaxo Presents Positive Breo Ellipta, Anoro Ellipta Data
05/18 GLAXOSMITHKLINE : How much should patients know about pharma payments to doctors..
05/18DJNovartis Says Drug-Unit Chief To Leave Firm -- WSJ
05/18 NOVARTIS : SPLITS BUSINESS Phama boss set to quit amid restructuring
05/17DJNovartis to Split Pharmaceuticals Division into Two -- Update
05/17DJNovartis to Split Drug Division
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials